Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 439 • 2019 ACR/ARP Annual Meeting
Improved Patient-Reported Outcomes in Patients with Persistently Active Rheumatoid Arthritis Following Treatment with Repository Corticotropin Injection
Daniel Furst¹, George Wan ², Jingyu Liu ³, Julie Zhu ³, Laura Bartels-Peculis ³, Mary Panaccio ³ and Roy Fleischmann ⁴, ¹University of California, Los Angeles, CA, ²Mallinckrodt Pharmaceuticals, Bedminster, NJ, ³Mallinckrodt Pharmaceuticals, ARD, LLC, Bedminster, NJ, ⁴Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disorder characterized by progressive inflammation and irreversible joint damage. Treatment of active disease includes disease-modifying anti-rheumatic drugs (DMARDs)…
Abstract Number: 464 • 2019 ACR/ARP Annual Meeting
Continuous Decrease in Serum RF Titer During Anti-TNF Therapy Was Associated with Suppression in Progression of RA Joint Damage
Takayoshi Owada¹, Kazuhiro Kurasawa ¹, Yuta Takamura ¹, Toshiyuki Miyao ¹, Ayae Tanaka ¹, Ryutaro Yamazaki ¹, Satoko Arai ¹, Reika Maezawa ¹ and Masafumi Arima ¹, ¹Dokkyo Medical University, Mibu-machi, Shimotsuga-gun, Tochigi, Japan
Background/Purpose: A number of studies have investigated the association between serum RF and joint damage in early and established RA patients, and positive and high-titer…
Abstract Number: 502 • 2019 ACR/ARP Annual Meeting
Disease Activity Measures at Baseline and 3 Months as Predictors of Rapid Radiographic Progression in Methotrexate Naïve Patients with Early Rheumatoid Arthritis
Mohammad Movahedi ¹, Deborah Weber ¹, Pooneh Akhavan ² and Edward Keystone³, ¹Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ²Division of Rheumatology, Mount Sinai Hospital, Toronto, Canada, ³Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Progressive rheumatoid arthritis (RA) is responsible for disabilities in this patient population, characterized by radiographic joint damage. Achieving low disease activity (LDA) in RA…
Abstract Number: 551 • 2019 ACR/ARP Annual Meeting
Upadacitinib Treatment and the Routine Assessment of Patient Index Data 3 (RAPID3) Among Patients with Rheumatoid Arthritis
Martin Bergman¹, Yoshiya Tanaka ², Gustavo Citera ³, Sami Bahlas ⁴, Mira Ali ⁵, Sebastian Meerwein ⁶, Yanna Song ⁷ and Vibeke Strand ⁸, ¹Drexel University College of Medicine, Stockholm, Sweden, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁴Medicine, King Abdulaziz University, Jeddah, Saudi Arabia, Jeddah, Saudi Arabia, ⁵AbbVie Inc., North Chicago, IL, USA, North Chiacgo, ⁶AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, ⁷AbbVie Inc., North Chicago, IL, USA, North Chicago, ⁸Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: Upadacitinib (UPA) is an oral reversible JAK inhibitor engineered for greater selectivity for JAK1 vs JAK2, JAK3, and TYK2, and is currently being assessed…
Abstract Number: 850 • 2019 ACR/ARP Annual Meeting
Safety of Synthetic and Biological DMARDs: A Systematic Literature Review Informing the 2019 Update of the EULAR Recommendations for Management of Rheumatoid Arthritis
Alexandre Sepriano¹, Andreas Kerschbaumer ², Josef Smolen ², Désirée van der Heijde ¹, Maxime Dougados ³, Ronald F Van Vollenhoven ⁴, Iain McInnes ⁵, Johannes Bijlsma ⁶, Gerd Burmester ⁷, Maarten de Wit ⁸, Louise Falzon ⁹ and Robert B.M. Landewé ¹⁰, ¹Leiden University Medical Center, Leiden, Netherlands, ²Medical University of Vienna, Vienna, Austria, ³Cochin Hospital, Paris, France, ⁴Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ⁵College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁶UMC Utrecht, Department of Rheumatology & Clinical Immunology, Utrecht, The Netherlands, Utrecht, Netherlands, ⁷Charité—University Medicine Berlin, Berlin, Germany, ⁸Department of Medical Humanities, Amsterdam Public Health (APH), Amsterdam University Medical Centre, Amsterdam, Netherlands, ⁹Northwell Health, New York, ¹⁰Amsterdam University Medical Center, Amsterdam, Netherlands
Background/Purpose: To assess the most recent safety-data of synthetic (s) and biological (b)DMARDs to inform the 2019 update of the EULAR recommendations for the management…
Abstract Number: 992 • 2019 ACR/ARP Annual Meeting
Identification of CJ-15314, a Novel Highly Selective JAK1 Inhibitor, for the Treatment of Rheumatoid Arthritis
So Young Ki¹, Dongkyu Kim ¹, Juhyun Lee ¹, Byoung Seok Moon ¹ and Shin-Young Ryu ¹, ¹CJ Healthcare, Icheon-si, Republic of Korea
Background/Purpose: Janus kinases (JAKs) play critical roles in mediating various cytokine signaling. First-generation non-selective JAK inhibitors such as tofacitinib and baricitinib are widely used for…
Abstract Number: 1211 • 2019 ACR/ARP Annual Meeting
Improving Exercise Counselling of Patients with Inflammatory Arthritis: A Quality Improvement Project
Anwar Albasri ¹, Tariq Al-Araimi ¹, Stephanie Gottheil¹, Lauren King ¹, Sahil Koppikar ², Justin Shamis ¹, Shirley Lake ³ and Gakhal Natasha ¹, ¹University of Toronto, Toronto, Canada, ²University of Toronto, Markham, ON, Canada, ³Division of Rheumatology, Sunnybrook Hospital, Toronto, ON, Canada
Background/Purpose: Regular aerobic exercise has been shown to improve inflammatory arthritis (IA) symptoms and may reduce the risk of cardiovascular events observed in these patients.…
Abstract Number: 1349 • 2019 ACR/ARP Annual Meeting
Earlier Biologic Initiation over Two Decades of Real World Observational Data from the RAPPORT Biologics Registry of Northern Alberta, Canada
Britney Jones¹, Bo Pan ¹, Joanne Homik ², Anthony Russell ², Walter P. Maksymowych ³, Jill Hall ¹ and Stephanie Keeling ¹, ¹University of Alberta, Edmonton, AB, Canada, ²University of Alberta, Edmonton, Canada, ³University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada
Background/Purpose: Rheumatoid (RA) and psoriatic arthritis (PsA) are inflammatory arthritides associated with significant potential functional disability if not well controlled. We reviewed the baseline demographic…
Abstract Number: 1379 • 2019 ACR/ARP Annual Meeting
Glucocorticoid Dose Is Progressively Reduced in Patients with RA Receiving Sarilumab: Results from the Open-Label EXTEND Study
Roy Fleischmann¹, Carlo Selmi ², Miguel Angel González-Gay ³, Hubert van Hoogstraten ⁴, Owen Hagino ⁴, Tejasweeni Rajput ⁵, Gregory St John ⁶, Frank Buttgereit ⁷ and Mark Genovese ⁸, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Humanitas Research Hospital, University of Milan, Milan, Italy, ³Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Sanofi, Bridgewater, NJ, ⁵Cytel, Mumbai, India, ⁶Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁷Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁸Stanford University, Stanford, CA
Background/Purpose: EXTEND (NCT01146652) is a long-term, open-label extension (OLE) study of sarilumab for the treatment of RA. This post hoc analysis assessed changes in oral…
Abstract Number: 1415 • 2019 ACR/ARP Annual Meeting
Effect of Tofacitinib on the Qualitative Profile of High Density Lipoproteins Molecules in Patients with Rheumatoid Arthritis
Aurelia Luissi¹, Florencia Pierini ², Ignacio Gandino ², Eliana Botta ³, Fernando Brites ³, Laura Boero ³, Maximiliano Martin ³, Tomas Meroño ³, Soledad saez ⁴, Walter Tetzlaff ³, Fernando Sommerfleck ⁵, Gustavo Citera ⁶, Javier Rosa ⁷, Patricia Sorroche ⁴ and Enrique Soriano ⁸, ¹Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Buenos Aires, Argentina, ²Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Capital Federal, Argentina, ³Universidad de Buenos Aires, Buenos Aires, Argentina, ⁴Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Sanatorio Mendez, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁶Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁷Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Argentina, ⁸Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Buenos Aires, Buenos Aires, Argentina
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk for cardiovascular diseases. Recent studies found that RA patients present dysfunctional high density lipoproteins (HDL)…
Abstract Number: 1770 • 2019 ACR/ARP Annual Meeting
Experimental Rheumatoid Joint Ameliorated by CRISPR Interference Targeting Long Non-coding RNA H19 Through Wnt Signaling Inactivation
Chrong-Reen Wang¹, Shih-Yao Chen ¹, Yu-Chi Chou ², Chao-Liang Wu ³, Yu-Ting Lo ¹ and Ai-Li Shiau ⁴, ¹National Cheng Kung University Hospital, Tainan, Taiwan (Republic of China), ²Genomics Research Center, Academia Sinica, Taipei, Taiwan (Republic of China), ³National Cheng Kung University Medical College, Tainan, Taiwan (Republic of China), ⁴National Cheng Kung University Medical College, Tainan, Taiwan (Republic of China)
Background/Purpose: Long non-coding RNAs (lncRNAs) participate in the rheumatoid arthritis (RA) pathogenesis. The aim of this study was to examine the lncRNA H19 and HOTAIR…
Abstract Number: 1894 • 2019 ACR/ARP Annual Meeting
Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Initiating Biologic and Non-biologic DMARDs, a Population-based Study
Lingyi Li¹, Na Lu ¹, Diane Lacaille ², Hui Xie ³, John Esdaile ⁴ and J. Antonio Avina-Zubieta ⁵, ¹Arthritis Research Canada, Vancouver, BC, Canada, ²Arthritis Research Canada and University of British Columbia, Vancouver, BC, Canada, ³Arthritis Research Canada and Simon Fraser University, Vancouver, BC, Canada, ⁴Arthritis Research Canada and the University of British Columbia, Richmond, BC, Canada, ⁵Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased risk of venous thromboembolism (VTE, which includes pulmonary embolism [PE] and deep vein thrombosis [DVT]) compared…
Abstract Number: 2015 • 2019 ACR/ARP Annual Meeting
Methotrexate Treatment Is Associated with Reduction of Neutrophil Reactive Oxygen Species and CD177 in RA Patients
Urvashi Kaundal ¹, Varun Dhir¹, Biman Saikia ¹ and Aastha Khullar ¹, ¹Post Graduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose: Methotrexate (MTX) is the gold-standard DMARD in rheumatoid arthritis, however, it is unclear how exactly it works. Its effects on neutrophils may involve reduction…
Abstract Number: 2238 • 2019 ACR/ARP Annual Meeting
Role of Clinical Impact, Disease-specific Knowledge and Beliefs About Medication on Therapeutic Adherence in Rheumatoid Arthritis: An Integrative Structural Equation Modeling Approach
George Karpouzas¹, Elizabeth Hernandez ², Lorena Ruiz ³, Vibeke Strand ⁴ and Sarah Ormseth ¹, ¹Harbor-UCLA Medical Center and Los Angeles Biomedical Institute, Torrance, CA, ²Harbor-UCLA and Los Angeles Biomedical Institute, Torrance, CA, ³Harbor-UCLA andLos Angeles Biomedical Research Institute, Torrance, ⁴Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: Treatment of rheumatoid arthritis (RA) to remission optimally ensures control of symptoms, prevention of structural damage, optimization of function and quality of life. Adherence…
Abstract Number: 2308 • 2019 ACR/ARP Annual Meeting
The Interaction Between Human Leukocyte Antigen Class II Alleles and Seroprotection to Seasonal Influenza Vaccination in Patients with Rheumatoid Arthritis: A post-hoc Analysis
Miriam Kim ¹, Jin Kyun Park ², Eun Bong Lee ³ and Kichul Shin⁴, ¹Seoul National University College of Medicine, Seoul, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, seoul, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, seoul, ⁴Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea., seoul, Republic of Korea
Background/Purpose: There are few studies that have looked into the role of human leukocyte antigen (HLA) class II alleles in seroprotection to influenza, especially in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].